pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,701 catalysts · 3,288 8k filing · 2,402 grant · 2,299 approval · 1,631 device 510k · 1,179 device recall · 1,115 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: grant×from 2025-10-08×clear all
type
  • 8k filing3,288
  • grant2,402
  • approval2,299
  • device 510k1,631
  • device recall1,179
  • device pma1,115
device adverse event
1,000
  • earnings584
  • recall465
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Oct 6, 2025

    50
    ›Oct 8, 2025approval310d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION

    full page →RIFADIN →fda approvals ↗
    ›Oct 8, 2025approval310d agoRIFATER (ISONIAZID) — FDA approvalRIFATER

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →RIFATER →fda approvals ↗
    ›Oct 8, 2025approval310d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: CAPSULE. Route: ORAL

    full page →RIFADIN →fda approvals ↗
    ›Oct 8, 2025approval310d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →amivantamab →fda approvals ↗
    ›Oct 8, 2025approval310d agoLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalcemiplimab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS

    full page →cemiplimab →fda approvals ↗
    ›Oct 8, 2025approval310d agoTRIAMCINOLONE ACETONIDE — FDA approvaltriamcinolone acetonide Rising

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INJECTION

    full page →triamcinolone acetonide Rising →fda approvals ↗
    ›Oct 8, 2025approval310d agoLUPKYNIS (VOCLOSPORIN) — FDA approvalvoclosporin

    Sponsor: AURINIA. Form: CAPSULE. Route: ORAL

    full page →voclosporin →fda approvals ↗
    ›Oct 8, 2025approval310d agoORGOVYX (RELUGOLIX) — FDA approvalrelugolix

    Sponsor: SUMITOMO PHARMA AM. Form: TABLET. Route: ORAL

    full page →relugolix →fda approvals ↗
    ›Oct 9, 2025approval309d agoSPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›Oct 9, 2025approval309d agoMORPHINE SULFATE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: UPSHER SMITH LABS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 9, 2025approval309d agoHYDROMORPHONE HYDROCHLORIDE — FDA approvalHYDROMORPHONE HYDROCHLORIDE

    Sponsor: ASCENT PHARMS INC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →HYDROMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Oct 9, 2025approval309d agoMORPHINE SULFATE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: IMPAX LABS INC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 9, 2025approval309d agoMORPHINE SULFATE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 9, 2025approval309d agoMORPHINE SULFATE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: ANDA REPOSITORY. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 9, 2025approval309d agoPRALUENT (ALIROCUMAB) — FDA approvalalirocumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →alirocumab →fda approvals ↗
    ›Oct 9, 2025approval309d agoCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalcabozantinib s-malate

    Sponsor: EXELIXIS INC. Form: TABLET. Route: ORAL

    full page →cabozantinib s-malate →fda approvals ↗
    ›Oct 9, 2025approval309d agoLOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Oct 9, 2025approval309d agoCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approvalcabozantinib s-malate

    Sponsor: EXELIXIS. Form: CAPSULE. Route: ORAL

    full page →cabozantinib s-malate →fda approvals ↗
    ›Oct 9, 2025approval309d agoTRAVATAN Z (TRAVOPROST) — FDA approvalTRAVOPROST

    Sponsor: SANDOZ. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →TRAVOPROST →fda approvals ↗
    ›Oct 9, 2025approval309d agoIXIFI (INFLIXIMAB-QBTX) — FDA approvalIXIFI

    Sponsor: PFIZER INC. Form: INJECTABLE. Route: INJECTION

    full page →IXIFI →fda approvals ↗
    ›Oct 9, 2025approval309d agoLOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: GRANULES. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Oct 9, 2025approval309d agoPEMETREXED DISODIUM — FDA approvalLilly USA LLC

    Sponsor: RELIANCE LIFE. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Oct 9, 2025approval309d agoZIPRASIDONE MESYLATE — FDA approvalZIPRASIDONE MESYLATE

    Sponsor: GLAND. Form: POWDER. Route: INTRAMUSCULAR

    full page →ZIPRASIDONE MESYLATE →fda approvals ↗
    ›Oct 9, 2025approval309d agoLANOXIN PEDIATRIC (DIGOXIN) — FDA approvalDIGOXIN

    Sponsor: AZURITY. Form: INJECTABLE. Route: INJECTION

    full page →DIGOXIN →fda approvals ↗
    ›Oct 9, 2025approval309d agoESCITALOPRAM OXALATE — FDA approvalAbbVie Inc.

    Sponsor: SUN PHARMA CANADA. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 9, 2025grant309d agoUNIVERSITY OF NEW MEXICO — Advancing precision medicine through measurement of reward and relief drinking

    AA grant. $39,309. PI: Hanna Marie Hebden

    full page →nih reporter ↗
    ›Oct 10, 2025approval308d agoISOVUE-250 (IOPAMIDOL) — FDA approval

    Sponsor: BRACCO. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoISOVUE-250 (IOPAMIDOL) — FDA approval

    Sponsor: BRACCO. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: TEVA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Oct 10, 2025approval308d agoMINOCYCLINE HYDROCHLORIDE — FDA approvalMINOCYCLINE HYDROCHLORIDE

    Sponsor: TORRENT. Form: CAPSULE. Route: ORAL

    full page →MINOCYCLINE HYDROCHLORIDE →fda approvals ↗
    ›Oct 10, 2025approval308d agoERRIN (NORETHINDRONE) — FDA approvalNaari USA Inc

    Sponsor: DR REDDYS LABS SA. Form: TABLET. Route: ORAL-28

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL ODT (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL ODT (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoUNITUXIN (DINUTUXIMAB) — FDA approvalUNITED THERAPEUTICS Corp

    Sponsor: UNITED THERAP. Form: INJECTABLE. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoUZEDY (RISPERIDONE) — FDA approvalDelpor Inc

    Sponsor: TEVA. Form: SUSPENSION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoUZEDY (RISPERIDONE) — FDA approvalDelpor Inc

    Sponsor: TEVA. Form: SUSPENSION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoGALLIUM GA 68 EDOTREOTIDE (GALLIUM GA-68 EDOTREOTIDE) — FDA approval

    Sponsor: METHODIST. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoRINVOQ LQ (UPADACITINIB) — FDA approvalupadacitinib

    Sponsor: ABBVIE. Form: SOLUTION. Route: ORAL

    full page →upadacitinib →fda approvals ↗
    ›Oct 10, 2025approval308d agoONGENTYS (OPICAPONE) — FDA approvalopicapone

    Sponsor: AMNEAL. Form: CAPSULE. Route: ORAL

    full page →opicapone →fda approvals ↗
    ›Oct 10, 2025approval308d agoOLPRUVA (SODIUM PHENYLBUTYRATE) — FDA approvalSODIUM PHENYLBUTYRATE

    Sponsor: ACER. Form: FOR SUSPENSION. Route: ORAL

    full page →SODIUM PHENYLBUTYRATE →fda approvals ↗
    ›Oct 10, 2025approval308d agoCHLORPROMAZINE HYDROCHLORIDE — FDA approvalFosun Pharma USA Inc

    Sponsor: RUBICON. Form: CONCENTRATE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL CD (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL CD (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approvalTakeda Pharmaceuticals USA Inc

    Sponsor: TAKEDA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoOLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalMicro Labs Ltd

    Sponsor: UMEDICA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL XR (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Oct 10, 2025approval308d agoLAMICTAL XR (LAMOTRIGINE) — FDA approvalLAMOTRIGINE

    Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ← prev
    page 1 of 95
    next →
    $REGN805.97+1.00%
    $ABBV250.82+0.83%
    $AUPH15.18-1.75%
    $ABBV250.82+0.83%
    $AMRX17.27-2.21%
    $PFE26.80+1.86%
    $UTHR501.27-2.04%
    $EXEL50.61+0.46%
    $EXEL50.61+0.46%
    $REGN805.97+1.00%
    $AMRX17.27-2.21%